Targeting the Src N-terminal regulatory element in cancer
We acknowledge extensive discussions with present and former members of the Pons’ group and the sustained collaboration with Serge Roche’s group in Montpellier. The Pons’ lab is financed by the Spanish Ministry of Science and Innovation (PID2019-104914RB-I00; PDC2021-121629-I00). The collaboration w...
| Autores: | , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:20.500.12328/3717 |
| Acceso en línea: | http://hdl.handle.net/20.500.12328/3717 https://dx.doi.org/10.18632/oncotarget.28434 |
| Access Level: | acceso abierto |
| Palabra clave: | Src quinases de la família Proteïnes intrínsecament desordenades SNRE Fàrmacs selectius de tipus cel·lular Resistència als fàrmacs Src quinasas de la familia Proteínas intrínsecamente desordenadas Fármacos selectivos de tipo celular Resistencia a las drogas Src family kinases Intrinsically disordered proteins Cell-type selective drugs Drug resistance 61 616 |
| Sumario: | We acknowledge extensive discussions with present and former members of the Pons’ group and the sustained collaboration with Serge Roche’s group in Montpellier. The Pons’ lab is financed by the Spanish Ministry of Science and Innovation (PID2019-104914RB-I00; PDC2021-121629-I00). The collaboration with the Roche group is financed by the French Agence Nationale de la Recherche (FUZZY-SRC ANR-21-CE13-0011). |
|---|